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ABSTRACT 
Current collaborative efforts in international research with developing countries are 
frequently paternalistic and deprive developing countries of the autonomy necessary to 
build independent research capacity. Developing countries have become progressively 
suspicious of the underlying intentions of corporate sponsored research as well as the 
motives behind research endeavors originated in developed countries that have minimal 
impact on the health care needs of their populations. The current trend towards 
globalization requires that certain standards be established to guide these collaborative 
efforts in order to create strong partnerships that promote global health in less developed 
countries. The objective of this paper is to present a comprehensive approach to health 
related international collaborative research with developing countries using as an 
example a model that has been developed in Colombia, S.A. that changes the prevailing 
paradigm of collaboration and promotes infant health. 
Specific Objectives 
• Summarize global aspects of neonatal and infant mortality. 
• Delineate the role of international collaborative research as a tool for enhancing 
autonomy and development. 
• Define the current paradigms for international collaborative research with developing 
countries. 
• Describe research productivity in Colombia through published peer-reviewed articles 
in Medline/Pubmed (2003-2005). 
• Identify areas of weakness in health research in Colombia. 
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• Paradigm change. Colombia a case in study. 
• Describe the role of trans-cultural and trans-continental virtual organizations for 
collaborative research and their challenges. 
• Describe the core competencies required to embark on successful collaborative efforts 
with developing countries. 
• Describe general ethical guidelines for conducting research collaborations in 
developing countries. 
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Introduction 
Almost II million children under 5 years of age die annually and more than 95% of 
these deaths occur in developing countries. 1·2 Approximately 38% of the total child 
mortality worldwide (4 million deaths) occurs in the first 4 weeks oflife, and 99% of 
these deaths arise in low-income and middle-income countries, yet most epidemiologic 
and other research focuses on the I% of deaths in higher income countries.3 A similar 
number are stillborn and 0.5 million mothers die from pregnancy-related causes. 1•3 
Between 1980 and 2000, child mortality after the first month of life fell by a third, 
whereas the neonatal mortality rate (NMR) was reduced by only a quarter. To meet the 
Millennium Developmental Goals (MDG-4), a substantial reduction in NMRs in high-
mortality countries is needed, and reducing deaths in the first week of life will be 
essential to progress.3 Globally, the main causes of neonatal death are preterm births 
(28%), severe infections (26%), and asphyxia (23%)3 It is in these three areas that public 
health, evidence based interventions, and local and international collaborative research 
efforts should focus their attention in order to decrease global neonatal and infant 
mortality. In addition to mortality, these three neonatal conditions cause considerable 
long term morbidity increasing the demand for services. 2 The absence of adequate 
follow-up and rehabilitation services has the potential to limit even further functional and 
cognitive development if these services are not provided concurrently with efforts to 
improve infant mortality. 
Governments, academic centers, and private organizations in both developed and 
developing countries are challenged to share a common vision in order to transition from 
passive observers of global health inequities to active participants in the process of 
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minimizing this problem. Those that have embraced the challenge through collaborative 
efforts have understood the potential deleterious effects of disregarding global health as a 
major concern for all nations. 
International collaborative research has the potential to facilitate the process of 
developing low-cost, high impact interventions as well as implementing evidence based 
interventions that are safe and efficacious (i.e., Kangaroo Mother Care, Oral 
Dehydration)4•5 as a means to decrease infant mortality in middle and low income 
countries. Combining resources from both developed and developing countries, if done 
appropriately, may promote the establishment of autonomous research capacity in 
developing countries that address the primary health problems of these high risk 
populations. Research aimed at improving health systems and identifying evidenced 
based interventions around the time of childbirth have the greatest potential to reduce 
neonatal mortality, stillbirths and maternal deaths? Furthermore, translating evidence-
based knowledge into public health policy and practice is essential to achieving this goal. 
This paper reviews the prevailing paradigm of international collaborative health 
research and presents a model that has been developed in Colombia, South America, for 
changing this paradigm to one that supports autonomy and development of research 
capacity. 
Prevailing paradigm 
To describe the current paradigm for international collaborative health research 
with developing countries, we must first identifY the underling mechanisms that originate 
and sustain it. For decades, research has been the privilege of developed countries, while 
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developing countries sit on the sidelines waiting for new and expensive technologies that 
eventually will be offered to a limited segment of their populations. In many cases these 
new technologies will not be marketed in developing countries because of socio-political 
obstacles, high cost and limited profits. 6 
Until recently, very little effort has been invested on the part of developed 
countries to promote research in developing countries. Of the global budget for health 
research, only 10% is spent on the disease burden of90% of the world's population 
(I 0/90 gap). 7 Best estimates are that the total spent on health research of any kind is 
around $70 billion US dollars. The National Institutes of Health (NIH) alone spent close 
to $27 billion on medical research in 2003. The pharmaceutical industry, 
overwhelmingly based either in the United States or the European Union, will spend 
about $30 billion. In all, less than $3 billion of funding originates from the poorer parts 
of the world. 7 Other factors that limit investment of research dollars in developing 
countries include: market constraints on drug research, language and logistic barriers, 
limited research capacity, inadequate administrative and accountability standards, and the 
stereotypic belief that research done in developing countries is poor quality research.8'9 
Because of limited resources, developing countries have traditionally assigned very small 
portions of their gross domestic product (GDP) to health care and research(< 4%), 
countries with the highest infant mortality rates spend on average 4.8% of their GDP on 
health care compared to 8.6% in countries with low infant mortality. 1 Recent studies 
have shown that the burden of disease in developing countries is high, particularly the 
burden of infectious, communicable and non-communicable disease and health problems 
of mothers and children. There is presently a mismatch between this health burden and 
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the technical and human capacity of developing countries to use existing knowledge and 
to generate new knowledge to overcome this burden. 8 
Because physicians in many developing countries are paid low wages and funding 
for career development and research is scarce, those interested in academia and research 
can only dedicate a small portion of their daily activities to these efforts or renounce 
entirely their pursuit of research as a career. Many investigators must moonlight in other 
jobs or do private practice to support their families, with inevitable effects on time 
available for research. 1° Full time academic researchers are far and few and economic 
decline and structural adjustment programs imposed on many developing countries have 
led to drastic cuts in numbers of academic staff and salary levels, and a lack of equipment 
and training opportunities. 10•11 Brain drain due to better standards ofliving and quality of 
life, higher salaries (in some cases 25 times higher), access to advanced technology and 
more stable political conditions in the developed countries attract talent from less 
developed areas. Increased momentum and demand for skilled people by high tech and 
research and development (R&D) industries accelerate flows of highly skilled workers to 
developed nations further depleting local research capacity. 11•12 Most of the migration of 
health professionals is occurring from countries with physician densities of about 17 per 
I 00,000 population to countries with densities of300 per I 00,000 populationY 
Developed countries unintentionally contribute to the prevalence of this paradigm 
by promoting models of collaborative research that are paternalistic and deprive 
developing countries of the support necessary to build and retain their own research 
capacity. Costello et a!. 10 believe that the prevailing research model supported by many 
funding agencies remains semicolonial in nature and that foreign domination in setting 
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research priorities and project management may have negative consequences which 
outweigh the apparent benefits of the research findings. Grant support for collaborative 
international research sponsored by government and private entities in developed 
countries in many cases require that the coordinating center be based in the developed 
country. While the previous approaches to collaboration may help assure funding 
agencies that high quality research will be developed and administrative requirements be 
fulfilled, it deprives developing countries of the support and autonomy to develop 
independent research capacity and to develop the expertise they will need to assure 
sustainability. 8•1 0 
Developing countries, on the other hand, have become progressively suspicious 
of the underlying intentions of collaborative and corporate sponsored research. 
Researchers from developed countries who embarked in collaborative efforts in many 
cases were motivated by scientific interests with limited or no relevance to the health care 
needs ofthe developing country. Such was the case of researchers from a prominent 
academic center in the United States that partnered with a pharmaceutical company to 
obtain biological samples in remote areas in Anhui Province, Central China, leading to 
international diplomatic disagreements about issues such as the ownership of genetic 
material and informed consent. 9•10• 13 Foreign researchers tend to favor efficacy trials of 
novel interventions, rather than applied studies to improve the transfer of proven 
interventions into rational health care policy and practice. 10 In many cases developing 
countries that have participated in these trials will not have access to these new and 
expensive interventions. A point in case is trastuzumab, a medication used for the 
treatment of breast cancer6 In other instances, foreign collaborators obtained knowledge 
8 
from international collaborative research efforts for their own personal and financial 
gains (i.e., ended berry for the treatment of schistosomiasis).9,14 Recently, "drug 
companies' quest for speedy results has led to a boom in trials based in developing 
countries, where ethical standards may be lax and the impoverished sick abundant." 15 
According to the U.S. Department of Health and Human Services Inspector General's 
office, the number of researchers based outside the United States seeking new drug 
approvals has increased 16-fold over the last decade. 15 This quest for speedy results has 
led to class-action suits against pharmaceutical companies like the one filed in 1996 by 
30 Nigerian families whose children participated in a trial of a new antibiotic for the 
treatment of meningitis without appropriate informed consent and safety control. 15 
Colombia, a case in study. 
Colombia's level of research and development (R&D) is low, even within the 
context of other Latin American and Caribbean nations. Acquisition of foreign 
technology is predominant; innovations are infrequent and occur mainly through 
incorporated technology while evidence-based knowledge is rarely transferred into 
technological development and innovation. 16 In Colombia, government funds for the 
development of research capacity are channeled through the Colombian Institute for the 
Development of Science and Technology (Colciencias). This organization is in charge of 
promoting research capacity through education and the creation and support of Master, 
Doctorate and Post-doctoral programs, support of existing research groups, grant support 
for research projects, promotion of international collaborations, and innovation and use of 
evidence-based knowledge. As a main objective, it strives to coordinate local research 
efforts among academic centers and the public and private sector with the goal of 
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transferring knowledge into policy and practice. In Colombia, as in other developing 
countries, goverrnnent institutions like Colciencias support research capacity through 
grants but their budgets are constrained, and stiff competition as well as goverrnnent 
priorities and red tape may deter local researchers from pursuing them. 
Investment in science, technology and innovation (CT +I) in 2003 was 0,38% of 
the GDP, with a current goal of increasing to 0.6% of GDP in 2006. 16 Colombia is 
currently a member of the "international network for information sources in science, 
technology and innovation (SCienT!). In 2002, two database systems were created 
(GrupLAC and CvLAC) to accumulate and process real time information to identify and 
monitor research capacity. Research groups were initially classified as recognized and 
registered. To further categorize them based on productivity and other qualitative 
variables, Colciencias in partnership with other research groups developed the ScientiCol 
Index which classifies research groups in three categories (A, B, and C) depending on 
length of existence of the group, the number and quality of publications produced per 
year, and the visibility and application of the results. Category A was defined as a 
ScientiCol index 2: 8 and at least 5 years of existence; category B, a ScientiCol index?:: 5 
and at least 3 years of existence; and category C, a ScientiCol index?:: 2 and at least 2 
years of existence. 17 Of the 1442 recognized research groups in 2003 and 2004, 774 
(53.7%) were classified according to these categories with 236 (30.5%) corresponding to 
category A, 276 (35.6%) to category B, and 262 (33.8%) to category C research groups. 
Of the 774 groups, 721 (93.1%) belonged to institutions of higher education, mostly 
public entities (52.7%). Medicine was the sub-area where research activity was more 
consolidated (77 research groups). 18 In 2006, a significant increase in research capacity 
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was observed with a total of2057 research groups identified. Of these, 547 were 
classified as category A and 447 (295 principal and 152 secondary) were identified as 
health sciences research groups with 176 dedicated exclusively to research in the sub-
area ofmedicine. 17•19 
Among 1500 approved projects by Colciencias during the period 1983 through 
1994, 129 (8.6%) had international collaboration (direct participation of one or more 
individuals from non-Colombian institutions). The total number of international 
collaborations was 210, mostly with the United States (36%), followed by Brazil and 
Spain. With respect to research productivity utilizing peer-reviewed publications as a 
means to measure quantitative and qualitative output, of the 119 articles in which authors 
from foreign institutions were identified as co-authors with Colombians during this 
period of 1983-1994, 90.7% were published in international journals.20 With respect to 
article production by field, 68% of total bibliometric output were projects in basic 
sciences (physics, chemistry, mathematics, biology and earth sciences [258 in national 
journals, 303 in international journals]). Only 2 articles in the health sciences were 
published in this period (0.24% [1 in a national journal and 1 in an international journal]) 
reflecting limited funding in this area.20 In 2005, health research funding by Colciencias 
was 6.5% (2.6 million USD) of its total budget ( 40.2 million USD); whether this amount 
of funding is balanced with the health science research needs of the nation is 
questionable.Z1 
To determine current bibliometric output in the health sciences in Colombia, the 
author (MAR) reviewed all publications published in peer-reviewed journals during the 
years 2003-2005. The word "Colombia" was used to identifY publications in 
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Medline/Pubmed. Categories were created to determine area of investigative focus, and 
to differentiate between papers published in English or Spanish peer-reviewed journals, 
and Colombian research groups (CRGs) versus foreign collaborative research groups 
(FCRGs) where Colombian researchers were invited participants (Table 1). Review 
articles and case studies were excluded from this analysis. A total of 539 peer-reviewed 
publications were identified during this period with an average of 180 publications per 
year. A similar proportion of publications in English and Spanish peer-reviewed journals 
were observed (310/539 [57.5%] versus 229/539 [42.5%]). Publications from CRGs (381 
[66.8%]) were superior in number to foreign collaborative research groups (187 [32.4%]). 
A predominance of research publications in the area of public health (population based 
studies) was observed (365/539 [67.7%]), followed by clinical research (156/539 
[28.9%], biomedical and genetic research (93/539 [17.2%]), and maternal and infant 
health research (61/539 [11.3%]). With respect to research design, in the year 2005, 
521108 (28.9%) cross sectional studies, 10/180 (5.5%) prospective cohort studies, and 
5/180 (2.8%) randomized controlled trials (RCTs) were identified. The remaining studies 
were predominantly descriptive. During that same year, the CNRN published one of the 
first multi-center RCT ever conducted in Colombia in the area ofneonatalogy.22 It is 
important to clarifY that this analysis did not take into account funding source nor was it 
clear whether international collaborative research publications were the result of 
structured ongoing collaborations or temporary collaborations. Also, the level of 
international collaboration may be underestimated because abstracts of manuscripts 
published in Colombian journals in most cases were not accompanied by a "full text" or 
PDF file limiting the possibility to ascertain foreign co-investigators in theses papers 
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(e.g., Biomedica, Revista de Salud Public [Bogota]). The previous description of 
bibliometric output from Colombia uncovers a paucity of innovative and evidence-based 
research in medicine. RCTs and research in the area of mother and infant health care 
were observed areas of weakness. Also, current controversy on the classification of 
research articles based on the non-scientific method of the "impact factor" by Colciencias 
has placed Medline/Pubmed indexed articles as second line publications with the 
potential to affect both the progress of scientific research and the income of academicians 
in public institutions in Colombia.23 
Paradigm Change 
In 1997 a collaborative research partnership was established between two 
Colombian researchers, one living in the United States and one in Colombia. Both 
researchers were Colombian pediatricians, one with subspecialty training in neonatal-
perinatal medicine and the other with a master in science degree. Both held faculty 
appointments in prestigious academic institutions in their respective country of residence 
(University of North Carolina, Chapel Hill and Pontificia Universidad Javeriana, 
Bogota). The vision and mission of this partnership was to improve the health of the 
neonatal population in Colombia through the design, implementation, and conduct of 
relevant research that could be translated into rational health care policy and practice. A 
major emphasis was made on using available research capacity in order to promote its 
development and sustainability. We propose a model developed in this country that 
changes the research paradigm to one that promotes the development of autonomous 
research capacity and scientific output through collaborative international team efforts. 
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In 1986 the Clinical Epidemiology and Biostatistics Unit (CEBU) at the 
Universidad Javeriana was established as one of three units in Colombia through grant 
support given by the International Clinical Epidemiology Network (INCLEN), an 
organization created by the Rockefeller Foundation to promote research capacity in 
developing countries. For the past 22 years, INCLEN has fulfilled its mission through 
the creation of clinical epidemiology units in over 50 academic institutions in 24 
countries around the world. It has also supported the training of over 450 graduates in 
clinical epidemiology, biostatistics, clinical economics, health management and other 
related social sciences.24 Currently, these units are in a transition process towards 
becoming self-sustainable organizations capable of competing for national and 
international grant support. These centers have the scientific and administrative 
capabilities to serve as coordinating centers for international collaborative research 
efforts. The Colombian based researcher (JML) has been involved with CEBU since its 
creation and is currently its director. This unit runs its own masters program in clinical 
epidemiology and recently has been upgraded to the level of department within the 
university and is classified as a category A research group according to the ScientiCol 
clasification. 17 Over the past 20 years CEBU has developed an extensive record of 
research productivity and international collaborations. 25 
Due to the paucity of experience with multi-center randomized controlled trials in 
the area of neonatology in Colombia, this collaborative group designed its first trial 
comparing two modes of ventilating near term and term infants with respiratory failure 
(conventional ventilation and high frequency oscillatory ventilation). Although a study 
of this magnitude was considered a high risk endeavor due to its complexity and cost, the 
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researchers felt that if successful, this study would also test the organizational skills and 
capabilities of the collaborative group. Two additional multi-center trials were 
subsequently implemented as a result of this partnership. 
Organizational structure of collaboration 
Due to the cross-national nature of this partnership, the collaborative group was 
structured as a virtual organization26 and specific roles were assigned to the different 
participants. The research infrastructure from academic institutions in both countries 
enabled collaborators to dedicate 30-40% of their academic time to project development 
while facilitating resources for communication, travel and educational enhancement 
(training in public health leadership). CEBU serves as the coordinating center for all 
research projects and is in charge oflocal coordination, training of research assistants, 
data collection, organization of educational workshops and data analysis. The Colombian 
researcher based in the United States (MAR) was assigned the responsibility of general 
coordination and project oversight, initial protocol design, project funding, development 
of educational workshops, data analysis and manuscript writing. Resources were pulled 
together from participating academic institutions to support this collaborative effort. 
These resources include but are not limited to biostatistician support, travel, 
communication, office supplies, and unexpected expenses. 
Both collaborators identified and visited potential participating hospital centers 
and physicians. Meetings were held to describe the projects and receive feedback in 
relation to general interest and feasibility of the studies. A separate meeting was set up to 
discuss research design and ethical issues. From these discussions a final draft of the 
project was elaborated that represented the consensus of all potential participants. Each 
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potential participant then submitted the study protocol to their respective Institutional 
Review Boards (IRBs). The projects were simultaneously submitted to the IRB of the 
University of North Carolina, Chapel Hill. Only centers with a letter of approval from 
their respective IRBs were permitted to participate. Safety review committees were setup 
during the conduct of RCTs to evaluate adverse events. Consent forms were written in 
English and then translated into Spanish with language that was culturally and age 
appropriate (6'h grade level). This methodology of collaborative work subsequently led 
to the creation of the Colombian Neonatal Research Network (CNRN), a conglomerate of 
14 participating academic and private institutions with neonatal nurseries. 
Communication 
Communication between countries is maintained through face to face visits that 
occur on average twice a year and may increase in number during the initial steps of 
study implementation and training. E-mail and telephone conversations, including 
conference calls are the main means of communication and are used selectively according 
to the nature of the problems that need discussion. Minimizing the cost of 
communications is balanced with the need to keep all parties well informed. A monthly 
update on recruitment, protocol violations, and adverse events is sent to each principal 
investigator by e-mail. Communication between public and private academic and non-
academic health care institutions in Colombia has also been enhanced through 
participation in the network's clinical trials. This was confirmed through their active 
participation and compliance during research meetings and workshops. 
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Funding for research projects 
Project funding has been obtained so far through grants from private industry 
where the bulk of the money is assigned to CEBU for project coordination and covers 
payment of research personal, paper work, transportation and miscellaneous. This 
approach was chosen to promote sustainability and the development of local research 
capacity. Data management and manuscript development is solely the responsibility of 
the principal investigators and conflicts of interest are disclosed prior to project 
implementation in order to avoid bias of participants. Overhead payments to the 
Pontificia Universidad Javeriana have been in the range of 15 to 25%. Remuneration for 
local research coordinators, associate research nurses and data collectors are paid 
according to Colombian government and institutional standards. Due to limited research 
dollars, researchers in the US have donated their time for project activities. This was 
deemed acceptable due to the large differences in academic remuneration between 
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administrative organization, CEBU and the CNRN are currently better positioned to 
compete for national and international funding. 
Research productivity 
To date the CNRN has successfully conducted 3 large multicenter studies, one 
prospective cohort study evaluating the epidemiology and risk factors for nosocomial 
infection in selected neonatal nurseries in Colombia, 27• 28 and two RCTs, the first 
described above,22 and the second, a study evaluating the use of prophylactic surfactant 
and nasal continuous positive airway pressure (NCP AP) in preterm infants with 
respiratory distress syndrome as a means to decrease the need for mechanical ventilation, 
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a more expensive and less available intervention that is associated with lung injury and 
the development of chronic lung disease (study in progress). A forth RCT in its funding 
phase will evaluate a low cost, high-impact intervention (probiotics) as a means to 
decrease nosocomial infection, Gram-negative sepsis, and necrotizing entercolitis in 
preterm infants. Participation in these trials has the potential to positively affect local 
patient care through standardization of interventions and general patient care among 
participating centers, as demonstrated in our first randomized controlled trial.22 
Perceived barriers 
The challenges of international collaborative research with developing countries 
are multiple and of variable complexity. Implementation and completion of research 
projects has been slower than expected for many reasons that include but are not limited 
to lack of experience with international collaborations, limited knowledge of virtual 
organizations, international law, local importation laws, equipment maintenance contracts 
and communication barriers. During the implementation of our first RCT in 1997, it was 
learned, that in Colombia, importation of equipment must be designated as "donated for 
research" to lower importation tariffs. In 2004, inexperience with customs regulations on 
one occasion led to a fine of over 5 million Colombian pesos (2, 173 USD). Retrieving 
equipment from customs was a long and tedious process that delayed patient recruitment. 
Identifying private suppliers of parts and maintenance of imported equipment was also a 
challenge that on several occasions led to temporary halting of randomization when 
research equipment required repairs. In many cases, parts had to be imported from the 
United States or Australia. These costs were all unbudgeted and reduced available 
research funds, making it imperative to petition for additional financial support. 
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,Additional unexpected events such as the 2005 earthquake in the city of Cali led to 
structural damage and temporary closure of one of our participating institutions, affecting 
overall patient recruitment and completion of a trial according to a planned and 
designated budget. 
Language and cultural barriers have not been a significant problem due to the 
common background of both Pis who have served as translators and communication 
facilitators between Colombian and American research participants. In Colombia, most 
physicians speak English fluently but this is not the case with nursing staff and other 
health care personnel. We have been fortunate to include in our research team a nurse 
research associate (MXR) and an MD research assistant (LC) that speak both languages. 
Their primary role is to oversee the conduct of research projects in the different cities 
where these studies are implemented. Both of them hold masters in clinical 
epidemiology obtained from CEBU and the Pontificia Universidad Javeriana. Excellent 
communication skills between research coordinators and other research personnel in the 
different participating centers have been fundamental to trial success. The multicenter 
nature of this organization demands additional resources, planning and flexibility. Over 
the years we have also learned to be more flexible with respect to timelines as we have 
come to understand the additional complexities of conducting research overseas. 
Intellectual ownership of the projects has been emphasized through the 
participation of all investigators in the different phases of project design, implementation, 
data analysis, and manuscript preparation. This has facilitated inclusion of all 
investigators from participating institutions in the authorship of manuscripts. This was 
perceived as an initial barrier due to limitations in the number of authors permitted by 
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different journals. However, this barrier was overcome by direct appeal to journals 
emphasizing the need to include all authors that participated in the trial, most of whom 
had no financial remuneration for their participation and accepted authorship as 
recognition for their efforts. We expect that in the future grant supported projects will 
cover a portion of their salaries. 
A specific challenge perceived through our research collaboration was the 
difficulty in coordinating cross-national activities between investigational review boards 
in both developed and developing countries. Lack of communication and differences in 
expectations require further interaction, training, and collaboration in order to assure 
compliance to international research standards while maintaining realistic expectations. 
This was made evident when translating the content of the consent form which was 
written according to American standards. Literal translation was not possible due to 
different cultural and legal contexts. A simplified version was developed by the 
coordinating center that met the expectations of their local IRB. This document was then 
included in the protocol for evaluation by IRBs from participating institutions. 
Institutional review boards in developed countries are challenged to acquire the 
appropriate competencies to interact with developing countries. We emphasize the 
process of thoughtful analysis and equal participation in the context of global health as 
the most appropriate path towards reaching consensus on the ethics of research. 
Differences in standards of care between private and public institutions in 
Colombia in some cases have led to the exclusion of potential participating institutions. 
Research in limited resource countries should permit the evaluation ofless expensive and 
innovative interventions that are traditionally not considered standard of care in 
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developed countries if these interventions are tested against recognized standard 
interventions. This was a perceived barrier during the conduct of our NCP AP trial in 
which some private hospitals considered this intervention a substandard method of care 
for infants with respiratory distress syndrome compared with intubation and mechanical 
ventilation even without objective data to support this belief. Effective communication, 
equipoise, and the availability of objective data to support research project 
implementation are fundamental to buy-in from all participants. It is also important to 
understand that "one can't simply declare that a disease is sufficiently researched just 
because it no longer has an impact on the affluent world." 29 Promoting the need for a 
global health approach to research among local institutions whether private or public may 
facilitate agreement on ethical standards for participation. 
As a collaborative research team, we questioned our motivations for participating 
in international collaborative research. Academic development was an important factor 
for all participants. But, the collective goal of promoting local research that would lead to 
evidence-based interventions and improved outcomes for the neonatal population in 
Colombia were the major driving force behind our effort. As a group we agreed that new 
technologies tested would be made available in all participating institutions. All 
technologies were donated by the private industry as research equipment to CEBU and 
the CNRN, and were subsequently maid available as a loan to participating institutions 
once proven to be safe and efficacious after the end of the trial. We considered this 
approach the most appropriate to avoid dependence on gifts and to have equipment 
available for future research projects. Testing new technologies in developing countries 
should be avoided if similar arrangements are not possible. Overcoming these barriers 
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has facilitated the implementation of subsequent projects; although, we are well aware 
that each research project comes with its own distinct challenges. 
Future directions 
From a public health perspective we are aware of the need to incorporate a 
maternal and perinatal component of research within our network in order to 
comprehensibly address the health care needs of both mothers and infants. We will do 
this through the design of studies that focus their attention on the care of the mother and 
infant around the time of birth. Through these projects we expect to expand our network 
to include researchers from the obstetric and maternal-fetal medicine disciplines. The 
observed lack of research productivity in maternal and infant health care in Colombia 
motivates us to become advocates for future enhancement. 
To improve the quality of research endeavors in Colombia, we will work towards 
improving communication among IRBs inside and outside of Colombia. This objective 
will be attained through sponsorship of educational workshops with international 
participation. Collaborative efforts in this area will be aimed at improving qualitative 
aspects of the IRB review process and will promote consistency in the ethical design and 
implementation of research with human subjects. 
CEBU and the CNRN are challenged to work in close proximity to the political 
process in order to transfer evidence-based knowledge into rational health care policy and 
practice. Publication of results in English and Spanish peer-reviewed journals and 
distribution of their results through the media, scientific meetings, and directly to 
government entities in charge of coordinating the Colombian health care system 
(Ministerio de Proteccion Social, Programa de Salud Matemo-Infantil, Secretarias de 
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Salud Departamentales, Entidades Promotoras de Salud) are a few examples of how to 
approach this problem. 
According to Flory et a!. 29 "a reformed research agenda is imperative to future 
progress in global health. Taking on the role of a scientist brings with it the responsibility 
of contributing to well-ordered science. In the presence of the 10/90 gap, there's ample 
reason to think that scientific research is not promoting its proper goal. Individual 
researchers and the institutions that fund them have an obligation to direct their research 
toward remedying the global research gap." 
Summary 
International collaborative research is an effective and efficient tool to promote 
autonomy, research capacity and scientific output in less developed countries if 
appropriately implemented. Knowledge of the dynamics of virtual organizations and 
cultural sensitivity are core competencies necessary for the success of these collaborative 
efforts. Emphasis should be placed on training future leaders that will promote 
collaborative research efforts that address the main health care needs of communities in 
developing countries. Creating strong partnerships based on mutual trust is fundamental 
to this objective. Supporting local research capacity will assure sustainability and 
ownership while limiting dependency. The Millennium Development Goals include 
recommendations for the creation of global partnerships to address the problems in 
maternal and infant health. 1 Decreasing the global health and research gap is the ultimate 
ethical imperative. 
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Colombian Neonatal Research Network Participants: 
Mario A. Rojas, MD, Vanderbilt University, Nashville, Tennessee; Juan M. Lozano, MD, 
MSc, Pontificia Universidad Javeriana, Bogota, Colombia; CarlL. Bose, MD, University 
of North Carolina, Chapel Hill, North Carolina, USA; Maria X. Rojas, RN Pontificia 
Universidad Javeriana; Martin Alonso Rondon, MSc, Pontificia Universidad Javeriana, 
Bogota, Colombia; Meica M. Efird, MD, MSPH, University of North Carolina, Chapel 
Hill, North Carolina, USA; Esperanza Pefia, RN, MSc, Pontificia Universidad Javeriana, 
Bogota, Colombia; Gloria Ruiz, MD, Pontificia Universidad Javeriana, Bogota, 
Colombia; Juan G. Pineros, MD, Fundaci6n Santa Fe de Bogota, Bogota, Colombia; 
Catherine Rojas, MD, Centro Policlinico del Olaya, Bogota, Colombia; Luz A. Celis, 
MD, Hospital Universitario Simon Bolivar; Guillermo Robayo, MD, Hospital 
Universitario Clinica San Rafael, Bogota, Colombia; Angela Hoyos, MD, Clinica del 
Country, Bogota, Colombia; Maria H. Gosendi, MD, Clinica San Pedro Claver, Bogota, 
Colombia; Heman Cruz, MD Fundaci6n Vaile de Lilli, Cali, Colombia; Angela Leon, 
MD, Hospital Universitario Simon Bolivar; Janet Correa, MD, Pontificia Universidad 
Javeriana; Sergio Torres, Centro Policlinico del Olaya, Bogota, Colombia; Reese Clark, 
MD, Duke University, Durham, North Carolina; Michael O'Shea, MD, Wake Forest 
University, Winston Salem, North Carolina USA; Luis A. Perez, MD, Hospital 
Universitario de Bucaramanga, Bucaramanga, Colombia; Jaime Bastides, MD, Clinica 
los Farallones, Cali, Colombia; Oscar Ovalle, Clinica Jorge Pifieros Corpas, SaludCoop, 
Bogota, Colombia; SensorMedics (Viasys Healthcare); Forest Laboratories; Ross-Abbott 
Laboratories; Fisher & Paykel Healthcare. 
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Research Productivity in Colombia Measured by Pear-Reviewed Publications 
Published in English and Spanish Journals (2003-2005) 
EPRJ SPRJ Total EJ SJ Total Total Public Clinical Biomedical 
CRG CRG CRGs FCRG FCRG FCRG Publications Health (%) and Genetic 
(%) (%) (%) (%) (%) (%) (100%) (%) Research 
(%) 
2003 48 66 114 53 10 63 177 61 48 37 
(27.1) (37.3) (64.4) (29.9) (5.6) (35.6) (34.5) (27.1) (20.9) 
2004 61 57 118 54 10 64 182 64 56 26 
(33.5) (31.3) (64.8) (29.6) (5.5) (35.2) (35.2) (30.8) (14.2) 
2005 61 73 134 33 13 46 180 82 52 30 
(33.9) (40.5) (74.5) (18.3) (7.2) (25.5) (45.5) (28.8) (16.6) 
PCRG, Colombian Research Group; FCRG, Fore1gn Collaborative Research Group; EPRJ, English 
peer- reviewed journal; SPRJ, Spanish peer-reviewed journal 
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Maternal-
infant 
Research 
(%) 
27 
(15.2) 
24 
(13.1) 
10 
(5.5) 
